Results of two Phase III studies of Bristol-Myers Squibb's oral TYK-2 inhibitor announced (with PPT)

Text | Pick up Bay

On April 23, Bristol-Myers Squibb (BMS) announced the positive results of two key Phase III clinical studies of its first-in-class oral, selective TYK2 inhibitor deucavacitinib in the treatment of moderate to severe plaque psoriasis.

Psoriasis is a widespread, chronic, and systemic immune-mediated disease that seriously affects the health, life and work of patients.

TYK2 is a member of the JAK family and plays an important role in mediating the signal transduction of pro-inflammatory cytokines (including IL-12, IL-23 and type I interferons).

Both the POETYK PSO-1 and POETYK PSO-2 studies are multicenter, randomized, double-blind controlled studies.

The results of the two studies showed that at week 16, 58.

In the two studies, 53.

In terms of safety, in the 16th week, the incidence of serious adverse events (SAEs) in the three groups of patients were 1.

In addition to being developed for the treatment of psoriasis, deucravacitinib has also been developed for the treatment of various immune diseases such as psoriatic arthritis, lupus erythematosus and inflammatory bowel disease.

Original title: Superior effect on Apster! Results of two Phase III studies of Bristol-Myers Squibb's first-in-class oral TYK-2 inhibitor announced (with PPT)